BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

(2012) Y. Imamura et al.   CLINICAL CANCER RESEARCH

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

(2012) X. Liao et al.   CLINICAL CANCER RESEARCH

Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer

(2012) Vlad Popovici et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas

(2012) Efsevia Vakiani et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

(2012) Hao-Wei Teng et al.   JOURNAL OF SURGICAL ONCOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

(2011) Ben Tran et al.   CANCER

Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

(2011) S. Ogino et al.   CLINICAL CANCER RESEARCH

Detection of KRAS and BRAF Mutations in Colorectal Carcinoma

(2011) Maria Arcila et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers

(2010) Yoshifumi Baba et al.   CANCER

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

(2009) V Catalano et al.   BRITISH JOURNAL OF CANCER

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT